Champions Oncology (CSBR) Stock: Buy, Sell, or Hold?
CSBR - Champions Oncology, Inc.
$4.72
-0.04 (-0.84%)
▼
5d:
+0.43%
30d:
-4.65%
90d:
-22.11%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Sep 21, 2026
0d
Get Alerted When CSBR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: CSBR shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: CSBR shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: CSBR is currently trading at $4.72, which is considered oversold relative to its 30-day fair value range of $4.77 to $5.08. From a valuation perspective, the stock is trading at a discount (Forward PE: 47.2) compared to its historical average (55.5). Remarkably, the market is currently pricing in an annual earnings decline of 5.3% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, CSBR is in a strong downtrend. The price is currently testing key support at $4.63. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CSBR scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $12.00 (+154.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CSBR is in a strong downtrend. The price is currently testing key support at $4.63. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CSBR scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $12.00 (+154.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$4.77 -
$5.08
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (38/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 154.2% below Wall St target ($12.00)
- WARNING: Composite score 49/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$4.77 -
$5.08
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$4.63
Resistance Level
$5.15
Current Trend
Strong Downtrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
47.20
Wall Street Target
$12.00
(+154.2%)
Revenue Growth (YoY)
8.8%
Earnings Growth (YoY)
-61.1%
Profit Margin
-1.9%
Valuation Discount vs History
-5.3% cheaper
PE vs Historical
47.2 vs 55.5
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-5.3%
(market-implied from PE analysis)
1-Year Target
$4.47
(-5%)
2-Year Target
$4.23
(-10%)
3-Year Target
$4.01
(-15%)
3-Yr Target (if PE normalizes)
(PE: 47→56)
$4.71
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 47.2, Growth: -16.7%)
$3.44
(+-27%)
Base:
(SPY PE: 19.9, Growth: -16.7%)
$1.45
(-69%)
Bear:
(PE: 16.9, Growth: -16.7%)
$1.23
(-74%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 47.2 to 55.5
Stabilization Target:
$5.55
(+17.6%)
PE Expansion Potential:
+17.6%
Share & Embed Analysis
Last updated: October 23, 2026 10:15 PM ET
Data refreshes hourly during market hours. Next update: 11:14 PM
Data refreshes hourly during market hours. Next update: 11:14 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CSBR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
25 analysts |
$1153 | 52 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
24 analysts |
$139 | 49 HOLD |
|
IRD
Opus Genetics, Inc. |
STRONG BUY
18 analysts |
$13 | 47 HOLD |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
17 analysts |
$141 | 52 HOLD |
|
RAPP
Rapport Therapeutics, In… |
STRONG BUY
16 analysts |
$63 | 54 HOLD |
